Hepatocellular Carcinoma: The Role of Interventional Oncology

Matteo Donadona \textsuperscript{a} Luigi Solbiati \textsuperscript{b} Laura Dawson \textsuperscript{c} Aisling Barry \textsuperscript{c} Gonzalo Sapisochin \textsuperscript{d} Paul D. Greig \textsuperscript{d} Shuichiro Shiina \textsuperscript{e} Andrea Fontana \textsuperscript{a} Guido Torzilli \textsuperscript{a}

\textsuperscript{a}Department of Hepatobiliary and General Surgery, Humanitas University, Humanitas Research Hospital IRCCS, \textsuperscript{b}Department of Interventional Radiology, Humanitas University, Humanitas Research Hospital IRCCS, Milan, Italy, \textsuperscript{c}Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, \textsuperscript{d}Departments of General Surgery and Multi Organ Transplantation, Toronto General Hospital, University of Toronto, Toronto, Canada, \textsuperscript{e}Department of Gastroenterology, Juntendo University Graduate School of Medicine, Tokyo, Japan

Key Words
IRE for HCC · MWA for HCC · Radiotherapy for HCC · RFA for HCC

Abstract

\textbf{Background:} Hepatocellular carcinoma (HCC) remains a major health issue because of its increasing incidence and because of the complexity of its management. In addition to the traditional potentially curative treatments, i.e., liver transplantation and surgical resection, other new and emerging local therapies have been applied with promising results.

\textbf{Summary:} Radiotherapy (RT) and interstitial treatments, such as radiofrequency ablation (RFA), microwave ablation (MWA), and irreversible electroporation (IRE), have recently opened new and interesting treatment scenarios for HCC and are associated with promising results in selected patients. Herein, we describe the emerging role of interventional oncology for the treatment of HCC and focus on the different Western and Eastern approaches.

\textbf{Key Messages:} Modern RT and modern interstitial therapies, such as RFA, MWA, and IRE, should be considered for inclusion in HCC therapy guidelines.

Copyright © 2016 S. Karger AG, Basel
Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related deaths worldwide [1]. Its treatment remains a major health issue because of its increasing incidence and because of the complexity of its management. In addition to liver transplantation and surgical resection, which are considered the standard of care for patients who satisfy specific inclusion criteria [2, 3], other new and emerging local therapies have been recently applied with promising results. The present work describes the emerging role of interventional oncology for the treatment of HCC.

Radiotherapy (RT) in the Management of HCC

Historically, since tumoricidal radiation doses cannot be delivered safely to the whole liver, radiation oncologists have shied away from managing HCC with RT because of fears of radiation-induced liver disease. The lingering fear of RT-associated toxicity may be attributable to past inferior and inefficient RT techniques requiring irradiation of the full liver by upper abdominal RT. However, with improved imaging technologies [multiphasic liver computed tomography (CT) and magnetic resonance imaging (MRI) and image registration software] and radiation technologies [from 3D conformal radiation therapy to stereotactic body radiotherapy (SBRT)], there has been a significant reduction in the volume of normal tissue exposed to radiation during treatment. As a result, there is great potential for ablative doses to be delivered to focal HCC of various stages, as long as sufficient liver may be spared from harmful exposure to radiation.

Liver RT uses multiphasic and multimodality imaging to develop a model of the lesion and of the adjacent organs, so that the prescribed doses of RT conform to the target volume; RT is most often delivered in 20–30 daily doses (fractions) over 4–7 weeks. SBRT, the most common RT treatment for HCC, applies a high dose of highly conformal radiation generally delivered in 3–6 treatment fractions over a far shorter time, in conjunction with breathing motion management strategies and daily image guidance at the time of RT delivery (IGRT). IGRT has been facilitated by the development of linear accelerators integrated with cone-beam CT; MRI integrated treatment units are under development and are planned for clinical use for liver cancer in 2016.

Similar to all HCC management strategies, hepatic RT is highly personalized. The irradiated volumes, tumor dose, number of fractions, breathing motion management strategy, and IGRT technique are dependent on patient factors (e.g., performance status and Child–Pugh score) and tumor factors (e.g., HCC size, number of lesions, location of lesions, and liver volume).

RT as a Bridge to Liver Transplantation

Up to 15% of newly diagnosed HCC patients are potentially curable with liver transplantation, which is the optimal therapy for HCC patients with underlying cirrhosis. Unfortunately, approximately 20–30% of these patients experience progression of their HCC while on the waiting list, rendering them unsuitable for transplantation. Bridging therapies are therefore often considered for patients with HCC during the pre-transplant wait period. Alternatively, for patients with HCC that exceeds size guidelines for transplantation, therapies are sometimes given with the goal of downstaging the HCC so that it falls within transplant guidelines (e.g., the Milan criteria).
Traditionally, transcatheter arterial chemoembolization (TACE) and RFA have been the most commonly used bridging or downstaging treatments. However, there is emerging interest in the use of RT, specifically SBRT, as a bridging therapy, especially for patients not well suited to RFA or TACE. Previous studies have shown the efficacy of SBRT as a bridge to liver transplantation [4–6]. Currently, at the University of Toronto, SBRT is being compared to TACE as a bridging therapy for HCC patients [7–10]. The preliminary analysis of that study (unpublished data) showed that of 311 patients with HCC listed for liver transplantation who underwent bridging therapy, 107 received either SBRT (n=23) or TACE (n=84). Patients in the SBRT group had more advanced liver disease that precluded TACE. No differences were observed between groups in the drop-out rate, in the actuarial survival after liver transplantation, or in the disease-free survival (DFS) after liver transplantation. Our ongoing analysis of 39 patients treated with SBRT as a bridge to transplantation suggests that SBRT (median dose 36 Gy in six fractions) can be delivered as a bridging therapy with no increase in toxicity at the time of transplantation.

**RT as a Potential Radical Treatment in Early and Intermediate Stage HCC**

Poor underlying liver function and/or comorbidities render the majority of HCC patients inoperable. Patients with small tumors (e.g., 3 cm) are best suited to RFA or local ablative treatments. Although TACE is the standard recommended treatment for patients unsuitable for RFA, TACE is not a curative treatment option. RT alone (without TACE) has been used with curative intent to treat early stage HCC, with promising outcomes (table 1).

Similar outcomes have been observed following proton RT [11], showing the potential for RT to achieve sustained control of HCC and improved long-term survival. These data indicate that for early stage HCC patients unsuitable for surgery, transplantation, RFA, or TACE, RT should be strongly considered; studies of RT in this setting in the Western world are much needed.

RT and TACE have also been delivered as planned combination therapy for early and intermediate stage HCC. Guo et al. [12] concluded that TACE alone was inferior to combination therapy: significantly higher response rates were evident for combination therapy than for TACE alone (47.4% vs 28.1%) and TACE combined with RT achieved overall survival (OS) rates at 1 and 3 years of 64.1% and 28.6%, respectively. Meng et al. [13] also showed superiority with combined TACE and RT in their meta-analysis of 1276 patients; however, well-designed phase III studies of TACE and RT have not been conducted.

### Table 1. Selected series of SBRT for early stage HCC

<table>
<thead>
<tr>
<th>Author, year [reference]</th>
<th>Patient number</th>
<th>Tumor size (cm)*</th>
<th>RT dose (Gy)</th>
<th>Number of fractions</th>
<th>Median follow-up (months)</th>
<th>1-Y OS</th>
<th>3-Y OS</th>
<th>≥ G3 hepatic toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanuki, 2013 [8]</td>
<td>185</td>
<td>2.5; 0.8–5</td>
<td>40</td>
<td>5</td>
<td>24</td>
<td>95%</td>
<td>70%</td>
<td>13%</td>
</tr>
<tr>
<td>Yoon, 2013 [9]</td>
<td>93</td>
<td>2; 1–6</td>
<td>30–40</td>
<td>3–4</td>
<td>25.6</td>
<td>86%</td>
<td>54%</td>
<td>6.5%</td>
</tr>
<tr>
<td>Kwon, 2010 [10]</td>
<td>42</td>
<td>15.4; 3–81.8</td>
<td>30–39</td>
<td>3</td>
<td>28.7</td>
<td>92%</td>
<td>58%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Y=year. *Values are the median and range.
RT for Locally Advanced HCC, Including Vascular Invasion and Disease Progression after TACE

There have been a number of SBRT series and phase II clinical trials that have investigated the use of RT alone to treat predominantly locally advanced HCC [11, 12]. Patients with recurrences following standard local regional therapies, those ineligible for standard therapies, and (less commonly) patients with a low burden of metastatic HCC, have been the focus of other RT studies. Studies have demonstrated high rates of local control, including control of vascular HCC, and promising survival rates, e.g., median survival of 17 months [14–16]. An example of a typical radiation plan for a patient with HCC and vascular invasion, and the subsequent response, is shown in fig. 1.

It is important to note that there is risk of a decline in liver function at 3 months (10–30%) in these patients. Thus, randomized controlled trials are essential in helping to understand the benefits versus the risks of RT in this setting.

RT in Conjunction with Chemotherapeutic Agents

TACE alone is not a curative therapy. However, Shim et al. [17] showed that TACE in conjunction with RT resulted in an increased 2-year survival of 36.8% vs 14.3% in patients with stage III or IVA disease. Survival rates have also been shown to improve from 7.9 to 10.2 months in patients with locally advanced unresectable HCC treated with sorafenib [18], the only molecular targeted agent approved in the management of locally advanced and metastatic HCC unsuitable for TACE. Evidence for a synergistic effect of RT and sorafenib therapy
[19] and the results of a phase II trial [20] have suggested that, compared to concurrent RT and sorafenib, sequential RT and sorafenib is an attractive strategy to improve tumor control while keeping the risk of additional toxicity to a minimum. These findings, and those of a series of SBRT alone, support RTOG 1112, a multi-institutional prospective randomized controlled trial to compare sorafenib alone and SBRT followed by sorafenib. RTOG 1112 is currently actively recruiting Child–Pugh A HCC patients who are unresectable or unsuitable for transplantation, resection, RFA, TACE, or drug-eluting bead therapy [21].

**RT as Palliation for Symptomatic HCC and Metastatic Disease**

Bleeding, pain related to a bulky tumor or rupture, and the prevention of pending tumor rupture are recognized indications for palliative RT in HCC patients. The use of RT in metastatic HCC (outside of the liver) is common, and the results are often beneficial because HCC is generally a radiation-responsive tumor. However, the data supporting the use of whole-liver low-dose RT for palliation of symptoms is limited. Using validated patient-reported outcomes, a recent phase II study demonstrated an improvement in symptoms at 1 month after single-dose RT (8 Gy in one fraction) in approximately 50% of patients with end-stage HCC causing substantial pain or discomfort [22]. This is promising and has prompted a phase III study (HE1) of palliative RT for symptomatic HCC and liver metastases that is currently recruiting [23]. This Canadian study will assess the quality of life and symptom control for highly symptomatic end-stage patients with HCC. Patients will be randomized to either RT alone or best supportive care, with an option to cross over at 1 month to receive RT for patients randomized to best supportive care. This study is powered to detect a large difference in symptom improvement from single-dose RT.

To summarize, the importance of RT at every stage of HCC management is increasing, even though the stigma associated with potential toxicity has stalled the development of randomized trials and the incorporation of RT into treatment guidelines.

**Interstitial Treatments: The Western Perspective**

In recent years, nonrandomized studies have reported similar outcomes for both the local control rate and OS for patients with very early stage HCCs (smaller than 2 cm) who underwent hepatic resection or ablation [24]. Accordingly, nodules in the 2-cm size range that are neither subcapsular nor perivascular are the ideal target for percutaneous ablation, which is considered to be the standard technique at most institutions. For such nodules, percutaneous ablation achieved a complete response rate approaching 97% and 5-year survival rates of 65–68% [25]. For patients with early stage HCC – either a single tumor smaller than 5 cm or up to three nodules each smaller than 3 cm, with no evidence of vascular invasion or extrahepatic spread, performance status 0, and class A or B cirrhosis – who can undergo any of the available curative therapies (i.e., surgical resection, liver transplantation, and image-guided ablation), the randomized trials comparing ablation and surgery reported to date have failed to demonstrate the superiority of either therapy. In general, when the first HCC develops, ablation is recommended when surgical options are precluded or severely challenging. However, for local tumor progression after resection and for distant recurrences (which occur in as many as 50–60% of patients with Hepatitis C Virus (HCV)-related cirrhosis during their lifetime), ablation is the first-line treatment when nodules are in a suitable and safe location for percutaneous targeting.

Recent reports on the long-term outcomes of patients treated with ablation have shown that in patients with Child–Pugh class A cirrhosis and early stage HCC, 5-year survival rates
are as high as 51–64% and may reach 76% in patients who meet the Barcelona Clinic Liver Cancer (BCLC) criteria for surgical resection [26–28]. Among the ablative methods, RFA still has the largest diffusion worldwide, but high-power-microwave (MW) technology, recently introduced to clinical practice, is able to overcome some specific limitations of RFA. Thanks to their physical properties, MWs achieve much higher tissue temperatures and, accordingly, achieve larger, more rounded, and regularly demarcated volumes of necrosis in a shorter time. Thus, in HCCs larger than 2–3 cm and/or multiple nodules, microwave ablation (MWA) has enabled a significantly increased rate of complete ablation compared to that achieved with RFA. MWA will likely lead to “raising the bar” for HCCs routinely treatable with ablation as an alternative to resection for HCCs from 2–3 cm, provided that the location is suitable and safe [29–31]. An additional clinically available ablative technique is irreversible electroporation (IRE). This approach opens new scenarios for the ablative treatment of small HCCs located in the vicinity of bile ducts or near the stomach, duodenum, or colon, i.e., in locations absolutely unsuitable for RFA.

Case series and cohort studies have demonstrated that locoregional therapies may reduce the drop-out rate of HCC patients on the waiting list for liver transplantation to 0–25%. For this purpose, RFA is the most commonly used bridging therapy in patients with a single HCC in a suitable location for percutaneous targeting, whereas MWA is chosen over RFA in cases with increased risk of heat-sink effects. TACE is also frequently used in the other cases, particularly when HCCs are multiple and bilobar.

Table 2 details the results of major Western series of HCC treated by MWA, RFA, or IRE [31–36]. As depicted, the results for MWA and RFA are comparable, whereas IRE is associated with inferior local control. However, the experience with IRE is still limited, and better results are expected in the future. Note that the long-term outcome (DFS and OS) associated with these three techniques are not truly comparable because the studies included different patient groups.

### Table 2. Results of the major Western series of HCC treated by MWA, RFA, or IRE

<table>
<thead>
<tr>
<th>Author, year [reference]</th>
<th>Number of patients/nodules</th>
<th>Tumor size (cm)*</th>
<th>CAR</th>
<th>LRR</th>
<th>1-Y DFS</th>
<th>5-Y DFS</th>
<th>1-Y OS</th>
<th>5-Y OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Niessen, 2016 [32]</td>
<td>IRE: 34/65</td>
<td>IRE: 2.4; 0.2–7.1</td>
<td>IRE: 81.5%</td>
<td>IRE: 35%</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Cannon, 2013 [33]</td>
<td>IRE: 14/18</td>
<td>IRE: 2.1; 1.3–4.5</td>
<td>IRE: 83%</td>
<td>IRE: 50%</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Cheung, 2013 [34]</td>
<td>IRE: 11/18</td>
<td>IRE: 2.0; 1.0–6.1</td>
<td>IRE: 72%</td>
<td>IRE: 0%</td>
<td>RFA: 96%</td>
<td>n.a.</td>
<td>n.a.</td>
<td>n.a.</td>
</tr>
<tr>
<td>Vogl, 2015 [31]</td>
<td>RFA: 25/32</td>
<td>RFA: 3.2; 0.8–4.5</td>
<td>RFA: 84%</td>
<td>RFA: 3%</td>
<td>n.a.</td>
<td>n.a.</td>
<td>100%</td>
<td>n.a.</td>
</tr>
<tr>
<td>Groeschl, 2014 [35]</td>
<td>MWA: 28/36</td>
<td>MWA: 2.6; 0.9–5</td>
<td>MWA: 89%</td>
<td>MWA: 3%</td>
<td>n.a.</td>
<td>MWA:</td>
<td>100%</td>
<td>MWA:</td>
</tr>
<tr>
<td>N’Kontcho, 2009 [36]</td>
<td>RFA: 235</td>
<td>RFA: 2.92; ±1**</td>
<td>RFA: 95%</td>
<td>RFA: 10%</td>
<td>n.a.</td>
<td>MWA:</td>
<td>19%</td>
<td>32%</td>
</tr>
</tbody>
</table>

CAR=complete ablation rate; LRR=local recurrence rate; n.a.= not available. *Values are the median and range; **Values are the mean and standard deviation.

CAR=complete ablation rate; LRR=local recurrence rate; n.a.= not available. *Values are the median and range; **Values are the mean and standard deviation.
Interstitial Treatments: The Eastern Perspective

Among the various nonsurgical therapies for HCC, image-guided percutaneous ablation is considered best for early stage HCC. Ablation has been widely performed in HCC patients, generally for those with Child–Pugh class A or B who have three or fewer tumors, each 3 cm or less in diameter. Ethanol injection (EI) was formerly the standard procedure among the various percutaneous ablation techniques [37]. However, randomized controlled trials have demonstrated that RFA is superior to EI. RFA has a 46% smaller risk of death (adjusted relative risk, 0.54 [95% CI: 0.33–0.89], p=0.02) and an 88% smaller risk of local tumor progression (relative risk, 0.12 [95% CI: 0.03–0.55], p=0.006) than EI does [38].

In the author's (SS) 10-year experience with RFA, final CTs showed complete tumor ablation in 2964 (99.4%) of 2982 treatments performed in 1170 primary HCC patients. With a median follow-up of 38.2 months, 5- and 10-year survival rates were 60.2% (95% CI 56.7–63.9%) and 27.3% (95% CI 21.5–34.7%), respectively. Multivariate analysis demonstrated that age, HCV infection, Child–Pugh class, tumor size, tumor number, the serum des-gamma-carboxy-prothrombin (DCP) level, and the serum lectin-reactive alpha-fetoprotein level (AFP-L3, one of the three AFP glycoforms which is highly specific for HCC even at early stage) were significantly related to survival. The 5- and 10-year local tumor progression rates (LTP) were both 3.2% (95% CI 2.1–4.3%). The serum DCP level alone was significantly related to local tumor progression. The 5- and 10-year distant recurrence rates were 74.8% (95% CI 71.8–77.8%) and 80.8% (95% CI 77.4–84.3%), respectively. HCV infection, Child–Pugh class, platelet count, tumor size, tumor number, serum AFP level, and serum DCP level were significantly related to distant recurrence [39]. Our results showed that RFA can be curative and can achieve long-term survival. A nationwide survey in Japan also showed similar OS between RFA and surgical resection.

Various innovations, such as contrast-enhanced ultrasound and multimodality fusion imaging, will likely further improve outcomes for percutaneous ablation. Sophisticated RFA is potentially curative, minimally invasive, and easily repeatable in case of recurrence, and might be superior to surgery in the treatment of small and middle-sized HCC.

Table 3 details the results of the major Eastern series of HCC treated by MWA and RFA. There is no experience with IRE in Eastern institutions. As with the Western experience, the results of MWA and RFA in terms of local control are comparable [39–44]. And again, the long-term outcomes (DFS and OS) of these studies were not comparable because they included different types of patients.

Conclusions

There is an emerging role for interventional oncology in the treatment of HCC, either as treatment alone, a bridge to transplantation, or associated with other approaches. Modern SBRT and interstitial therapies such as RFA, MWA, and IRE deserve consideration for inclusion in therapy guidelines, and not just for early HCC.
Table 3. Results of the major Eastern series of HCC treated by MWA or RFA

<table>
<thead>
<tr>
<th>Author, year [reference]</th>
<th>Number of patients/nodules</th>
<th>Tumor size (cm)*</th>
<th>CAR</th>
<th>LTP</th>
<th>1-Y DFS</th>
<th>5-Y DFS</th>
<th>1-Y OS</th>
<th>5-Y OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang, 2013 [40]</td>
<td>RFA: 78/97 MWA: 77/105</td>
<td>RFA: 2.3; 0.8–5</td>
<td>RFA: 83% 12%</td>
<td>RFA: 70% 62%</td>
<td>RFA: 91% 21%</td>
<td>RFA: 41% 38%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ding, 2013 [41]</td>
<td>RFA: 85/98 MWA: 113/131</td>
<td>RFA: 2.38; 0.8–5</td>
<td>RFA: 99% 80%</td>
<td>RFA: 19% 75%</td>
<td>RFA: 99% 68%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shiina, 2012 [39]</td>
<td>RFA: 1170/2982</td>
<td>RFA: 2.54 ± 1.04**</td>
<td>RFA: 99% 10%</td>
<td>RFA: 73% 16%</td>
<td>RFA: 97% 70%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ohmoto, 2009 [42]</td>
<td>RFA: 34/37 MWA: 49/56</td>
<td>RFA: 1.6; 0.7–2</td>
<td>RFA: 9% 63%</td>
<td>RFA: 26% 3%</td>
<td>RFA: 100% 89%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lu, 2005 [43]</td>
<td>RFA: 53/98 MWA: 49/72</td>
<td>RFA: 2.6; 1–6.1</td>
<td>RFA: 93% 21%</td>
<td>RFA: 37% 46%</td>
<td>RFA: 60% 24%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shibata, 2002 [44]</td>
<td>RFA: 36/48 MWA: 36/46</td>
<td>RFA: 2.3; 1–3.7</td>
<td>RFA: 96% 12%</td>
<td>RFA: 82% 24%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CAR=complete ablation rate. *Values are the median and range; **Values are the mean and standard deviation.

Conflicts of Interest

The authors declare no conflicts of interest.

References


